Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.
OBJECTIVE
Switching patients with Alzheimer's disease from one cholinesterase inhibitor to another represents a viable option for patients not responding to current therapy. The objective of this large U.S.-based study was to evaluate the safety and efficacy of a treatment switch to rivastigmine in patients not responding adequately to or declining on treatment with donepezil.


METHODS
In this 26-week, prospective, open-label, single-arm, multicenter study conducted from April 24, 2003, to June 25, 2004, patients with mild-to-moderate Alzheimer's disease (DSM-IV-TR criteria) who were not responding to donepezil were treated with rivastigmine 3-12 mg/day. Safety and tolerability were measured by the occurrence of adverse events and patient disposition. Treatment effects on global functioning were assessed using the Clinical Global Impression of Change (CGIC) scale.


RESULTS
Two hundred seventy patients with a mean age of 78.5 (SD = 7.56) years and a mean duration of dementia of 3.5 (SD = 2.06) years were included in the study. Sixty-nine percent of patients completed the study with 17.8% discontinuing due to adverse events. Eighty-three percent of patients reported at least 1 adverse event, with the most frequently occurring adverse events affecting the gastrointestinal system (54%). The majority of patients were reported to have either improvement or no decline on the CGIC. A limitation of the study is that the interpretation of the results is based on an overall completion rate of 69%.


CONCLUSIONS
Immediately switching patients from donepezil to rivastigmine without a washout period was safe and well tolerated in the current study. Additionally, these results suggest that patients not responding adequately to or declining while taking donepezil may improve or stabilize after switching to rivastigmine.
Figiel
Gary S
GS
Southeastern Geriatric Healthcare Group, Snellville, Ga, USA.
Sadowsky
Carl H
CH
Strigas
John
J
Koumaras
Barbara
B
Meng
Xiangyi
X
Gunay
Ibrahim
I
Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):131-45
12611743
J Am Osteopath Assoc. 2005 Mar;105(3):145-58
15863734
Neurology. 2001 May 8;56(9):1154-66
11342679
Curr Med Res Opin. 2002;18(3):129-38
12094822
Int J Clin Pract. 2006 Jan;60(1):110-8
16409439
Arch Neurol. 2001 Mar;58(3):427-33
11255446
Prim Care Companion J Clin Psychiatry. 2005;7(2):43-48
15841194
Curr Med Res Opin. 2003;19(8):707-14
14687441
Neurology. 1984 Jul;34(7):939-44
6610841
Arch Intern Med. 1998 May 11;158(9):1021-31
9588436
Gerontologist. 1991 Feb;31(1):76-83
2007478
Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):186-94
16327345
Neurology. 1998 Jan;50(1):136-45
9443470
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Int J Geriatr Psychiatry. 2002 Mar;17(3):288-9
11921158
Arch Neurol. 2000 Jan;57(1):94-9
10634454
Neurology. 1994 Dec;44(12):2308-14
7991117